Enhanced transdermal absorption and pharmacokinetic evaluation of pranoprofen-ethylene-vinyl acetate matrix containing penetration enhancer in rats

被引:6
作者
Cho, Cheong-Weon [2 ]
Choi, Jun-Shik [3 ]
Yang, Kyu-Ho [4 ,5 ]
Shin, Sang-Chul [1 ]
机构
[1] Chonnam Natl Univ, Coll Pharm, Kwangju 500757, South Korea
[2] Chungnam Natl Univ, Coll Pharm, Taejon 305764, South Korea
[3] Chosun Univ, Coll Pharm, Kwangju 501759, South Korea
[4] Chonnam Natl Univ, Sch Dent, Dent Res Inst, Kwangju 500757, South Korea
[5] Chonnam Natl Univ, Sch Dent, Stage BK 21 2, Kwangju 500757, South Korea
关键词
Pranoprofen; Ethylene-vinyl acetate matrix; Penetration enhancer; Bioavailability; Pharmacokinetics; Transdermal administration; SKIN PERMEATION; CONTROLLED-RELEASE; DELIVERY; ACIDS;
D O I
10.1007/s12272-009-1514-5
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
To increase the skin permeation of pranoprofen from the ethylene-vinyl acetate (EVA) matrix, different types of enhancers were added to an EVA matrix containing 2% pranoprofen. The pharmacokinetics and bioavailability of pranoprofen, an anti-inflammatory drug, were examined to determine the feasibility of an enhanced transdermal delivery system for pranoprofen from an EVA matrix containing caprylic acid as the enhancer in rats. The effects of the enhancers on the level of pranoprofen permeation through the skin were evaluated using Franz diffusion cells that were fitted with the intact excised rat skin. Among the enhancers used, including the fatty acids (saturated, unsaturated), the glycols, the glycerides, and the pyrrolidones, caprylic acid showed the best enhancement. A pranoprofen-EVA matrix system was formulated containing caprylic acid as an enhancer. The pranoprofen-EVA matrix system (8 mg/kg) was applied to the abdominal skin of rats. The blood samples were collected through the femoral artery for 24 h and the plasma concentrations of pranoprofen were determined by HPLC. The pharmacokinetic parameters were calculated using the MULTI computer program. The area under the curve (AUC) was significantly higher in the enhancer group (55.49 +/- 13.87 ng/mL center dot h) than in the control group (22.48 +/- 5.63 ng/mL center dot h), which was treated transdermally without the enhancer, showing about 246% increased bioavailability (p < 0.05). As the pranoprofen-EVA matrix containing caprylic acid as an enhancer was administered to rats via the transdermal routes, the relative bioavailability increased about 2.46-fold compared to the control group, showing a relatively constant, sustained blood concentration. These results show that a pranoprofen-EVA matrix containing a permeation enhancer could be developed as a transdermal delivery system to provide a sustained plasma concentration.
引用
收藏
页码:747 / 753
页数:7
相关论文
共 22 条
[1]   EFFECTS OF VITAMIN-E AND SQUALENE ON SKIN IRRITATION OF A TRANSDERMAL ABSORPTION ENHANCER, LAUROYLSARCOSINE [J].
AIOI, A ;
KURIYAMA, K ;
SHIMIZU, T ;
YOSHIOKA, M ;
UENOYAMA, S .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1993, 93 (1-3) :1-6
[2]   Skin permeation of propranolol from polymeric film containing terpene enhancers for transdermal use [J].
Amnuaikit, C ;
Ikeuchi, I ;
Ogawara, K ;
Higaki, K ;
Kimura, T .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2005, 289 (1-2) :167-178
[3]   Effect of penetration enhancers on the release and skin permeation of bupranolol from reservoir-type transdermal delivery systems [J].
Babu, RJ ;
Pandit, JK .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2005, 288 (02) :325-334
[4]   BILE-ACIDS AS ENHANCERS OF STEROID PENETRATION THROUGH EXCISED HAIRLESS MOUSE SKIN [J].
CARELLI, V ;
DICOLO, G ;
NANNIPIERI, E ;
SERAFINI, MF .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1993, 89 (02) :81-89
[5]   Controlled release of pranoprofen from the ethylene-vinyl acetate matrix using plasticizer [J].
Cho, Cheong-Weon ;
Choi, Jun-Shik ;
Shin, Sang-Chul .
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2007, 33 (07) :747-753
[6]  
GENNARO AR, 1995, REMINGTON SCI PRACTI, P1207
[7]   Structure-activity relationship of chemical penetration enhancers in transdermal drug delivery [J].
Kanikkannan, N ;
Kandimalla, K ;
Lamba, SS ;
Singh, M .
CURRENT MEDICINAL CHEMISTRY, 2000, 7 (06) :593-608
[8]   The correlation between transepidermal water loss and percutaneous absorption: An overview [J].
Levin, J ;
Maibach, H .
JOURNAL OF CONTROLLED RELEASE, 2005, 103 (02) :291-299
[9]   Evaluation of transcutol as a clonazepam transdermal permeation enhancer from hydrophilic gel formulations [J].
Mura, P ;
Faucci, MT ;
Bramanti, G ;
Corti, P .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2000, 9 (04) :365-372
[10]   In vitro release studies on matrix type transdermal drug delivery system of naltrexone and its acetyl prodrug [J].
Nalluri, BN ;
Milligan, C ;
Chen, JH ;
Crooks, PA ;
Stinchcomb, AL .
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2005, 31 (09) :871-877